Drug profile · INN
trofinetide
DAYBU
trofinetide (DAYBU) is a unknown. Associated with Acadia Pharmaceuticals B.V.. Route of administration: oral. Current US regulatory status: approved.
Drug details — trofinetide
- US status
- approved
- Class
- Nervous system (N07)
- Route
- ORAL
- Patents
- 20
- Programs
- 1
- Data quality
- 0.89
Quick answer
trofinetide (DAYBU) is a unknown. Associated with Acadia Pharmaceuticals B.V.. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Unknown
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | unknown | — |
Pipeline programs
Related & competitor drugs
Related patents
-
US 11844764
Agitation process for preparing a carbetocin drug product
granted -
US 11827600
Crystalline forms of trofinetide
granted -
US 10525046
Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases
granted -
US 10028944
Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases
granted -
US 9670209
Muscarinic agonists
granted -
US 9566271
Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases
granted -
US 9522906
Tetrahydroquinoline analogues as muscarinic agonists
granted -
US 9296694
Azacyclic compounds
granted -
US 9211289
Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases
granted -
US 8921393
Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases
granted -
US 8680115
Tetrahydroquinoline analogues as muscarinic agonists
granted -
US 8618130
Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases
granted -
US 8377959
Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases
granted -
US 8227487
Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases
granted -
US 8008323
Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases
granted -
US 7994193
Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases
granted -
US 7875632
Selective serotonin receptor inverse agonists as therapeutics for disease
granted -
US 7868176
Salts of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-y1)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and their preparation
granted -
US 7863296
Selective serotonin receptor inverse agonists as therapeutics for disease
granted -
US 7820695
Selective serotonin receptor inverse agonists as therapeutics for disease
granted
Frequently asked questions
What is trofinetide?
trofinetide (DAYBU) is a unknown. Associated with Acadia Pharmaceuticals B.V.. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for trofinetide?
DAYBU is a marketed brand name for trofinetide. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of trofinetide?
trofinetide has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.